Alembic Pharmaceuticals Limited (APLLTD.NS)
INR 846.4
(0.73%)
INR 846.4
(0.73%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.27 Billion INR | -10.21% |
| 2022 | 18.12 Billion INR | -3.83% |
| 2021 | 18.84 Billion INR | 14.77% |
| 2020 | 16.42 Billion INR | -41.33% |
| 2019 | 27.98 Billion INR | 35.87% |
| 2018 | 20.59 Billion INR | 19.71% |
| 2017 | 17.2 Billion INR | 119.06% |
| 2016 | 7.85 Billion INR | -8.54% |
| 2015 | 8.58 Billion INR | 13.52% |
| 2014 | 7.56 Billion INR | 39.52% |
| 2013 | 5.42 Billion INR | -0.49% |
| 2012 | 5.44 Billion INR | -17.05% |
| 2011 | 6.56 Billion INR | 19.79% |
| 2010 | 5.48 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -48.18 Billion INR | -396.07% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 19.85 Billion INR | 0.0% |
| 2023 Q4 | 16.27 Billion INR | 0.0% |
| 2023 FY | 16.27 Billion INR | -10.21% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 18.12 Billion INR | -3.83% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 19.78 Billion INR | 0.0% |
| 2022 Q4 | 18.12 Billion INR | 0.0% |
| 2021 Q4 | 18.84 Billion INR | 0.0% |
| 2021 FY | 18.84 Billion INR | 14.77% |
| 2021 Q2 | 20.2 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q4 | 16.42 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 18.01 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 16.42 Billion INR | -41.33% |
| 2019 FY | 27.98 Billion INR | 35.87% |
| 2019 Q2 | 26.46 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 27.98 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 Q2 | 23.71 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q4 | 20.59 Billion INR | 0.0% |
| 2018 FY | 20.59 Billion INR | 19.71% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 17.2 Billion INR | 119.06% |
| 2017 Q4 | 17.2 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 13.53 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 7.85 Billion INR | 0.0% |
| 2016 Q2 | 10.2 Billion INR | 0.0% |
| 2016 FY | 7.85 Billion INR | -8.54% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 8.58 Billion INR | 0.0% |
| 2015 Q2 | 7.9 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 8.58 Billion INR | 13.52% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 6.98 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 7.56 Billion INR | 39.52% |
| 2014 Q4 | 7.56 Billion INR | 0.0% |
| 2013 FY | 5.42 Billion INR | -0.49% |
| 2013 Q4 | 5.42 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 5.65 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q4 | 5.44 Billion INR | 0.0% |
| 2012 FY | 5.44 Billion INR | -17.05% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 12.16 Billion INR | 0.0% |
| 2011 FY | 6.56 Billion INR | 19.79% |
| 2010 FY | 5.48 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Hester Biosciences Limited | 3.59 Billion INR | -352.714% |
| Aarti Drugs Limited | 11.5 Billion INR | -41.462% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -97.241% |
| Albert David Limited | 1.15 Billion INR | -1314.984% |
| Alembic Limited | 1.43 Billion INR | -1036.359% |
| Alkem Laboratories Limited | 48.6 Billion INR | 66.518% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -2394.914% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -234.324% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -5534.992% |
| Brooks Laboratories Limited | 248.6 Million INR | -6446.152% |
| Eris Lifesciences Limited | 38.26 Billion INR | 57.474% |
| FDC Limited | 3.7 Billion INR | -338.741% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -214.111% |
| Gufic Biosciences Limited | 5.59 Billion INR | -190.613% |
| Hikal Limited | 12.99 Billion INR | -25.232% |
| Ind-Swift Limited | 13.45 Billion INR | -20.968% |
| Innova Captab Limited | 4.89 Billion INR | -232.127% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -157.135% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -5383.825% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 73.441% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -1414.483% |
| Lupin Limited | 96.23 Billion INR | 83.09% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -723.443% |
| Medico Remedies Limited | 438.24 Million INR | -3613.411% |
| Morepen Laboratories Limited | 4.45 Billion INR | -264.901% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -45.068% |
| Orchid Pharma Limited | 3.84 Billion INR | -323.347% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -535.397% |
| RPG Life Sciences Limited | 1.38 Billion INR | -1079.09% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -2427.447% |
| Sigachi Industries Limited | 2.53 Billion INR | -542.912% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -15.484% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -699.998% |
| Themis Medicare Limited | 1.88 Billion INR | -762.183% |
| Unichem Laboratories Limited | 8.06 Billion INR | -101.677% |
| Vaishali Pharma Limited | 371.16 Million INR | -4284.543% |
| Wanbury Limited | 3.15 Billion INR | -415.725% |
| Windlas Biotech Limited | 1.76 Billion INR | -823.231% |
| ZIM Laboratories Limited | 2.08 Billion INR | -682.108% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -610.814% |
| Ipca Laboratories Limited | 33.74 Billion INR | 51.771% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 91.135% |
| Venus Remedies Limited | 1.39 Billion INR | -1068.423% |
| Sakar Healthcare Limited | 1.26 Billion INR | -1188.218% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 89.308% |
| Divi's Laboratories Limited | 18.99 Billion INR | 14.303% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -344.505% |
| Mankind Pharma Limited | 23.87 Billion INR | 31.837% |
| Sequent Scientific Limited | 8.27 Billion INR | -96.68% |
| Laurus Labs Limited | 42.71 Billion INR | 61.901% |
| Neuland Laboratories Limited | 5.49 Billion INR | -195.965% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -51.978% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 75.006% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 77.332% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -1976.206% |
| Wockhardt Limited | 39.87 Billion INR | 59.183% |
| Bal Pharma Limited | 2.51 Billion INR | -548.029% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 84.786% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -671.69% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -10084.428% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -364.223% |
| Shilpa Medicare Limited | 12.93 Billion INR | -25.837% |
| Valiant Laboratories Limited | 1.05 Billion INR | -1437.787% |
| Ajanta Pharma Limited | 10.71 Billion INR | -51.945% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -844.949% |
| Granules India Limited | 22.95 Billion INR | 29.104% |
| Medicamen Biotech Limited | 940.36 Million INR | -1630.58% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -1296.64% |
| Piramal Enterprises Limited | 560.47 Billion INR | 97.096% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 80.166% |
| NATCO Pharma Limited | 10.53 Billion INR | -54.518% |
| Suven Life Sciences Limited | 148.62 Million INR | -10849.866% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -447.218% |
| Strides Pharma Science Limited | 37.68 Billion INR | 56.811% |
| Indoco Remedies Limited | 10.34 Billion INR | -57.352% |
| Alpa Laboratories Limited | 307.12 Million INR | -5198.806% |
| Lasa Supergenerics Limited | 541.92 Million INR | -2902.962% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -318.038% |